Bayer : Q2 a strong beat on CropScience, but no change to FY guidance
>Adj. EBITDA 12-13% above our forecast and consensus…. - Bayer had a strong start to FY 2022 with revenues having been up by c. 19% y-o-y and adj. EBITDA by c. 28% y-o-y. This was 6-7% better than our forecast and the consensus (Vara) on revenues and even 12-13% better on adj. EBITDA. FX had a c. +4.4% impact on revenues vs 4% estimated. Adj. EPS of € 3.53 came in c.13% ahead of our forecast and c. 18% better than consensus. This beat was due to CropScience, which sho...Bayer is a life sciences group based in Germany. Co.'s operations are organized along three divisions: Pharmaceuticals (engaged in prescription pharmaceuticals for cardiology and women's healthcare); Consumer Health (engaged in non-prescription products in dermatology, dietary supplement, analgesic, gastrointestinal, allergy, cold and flu, foot care, sun protection and cardiovascular risk prevention categories); and CropScience (engaged in the development of seeds and plant traits; crop protection; and for gardens, the green industry and non-agricultural pest control). Co. also maintains an Animal Health business unit engaged in the development of products for farm and companion animals.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.